CALDRE AG
CALDRE develops innovative liver disease therapeutics.
CALDRE is a University of Bern spin-out developing ClagalsiR, a GalNAc-siRNA for cholestatic and fibrotic liver diseases affecting more than 370,000 patients in major markets. Many lack effective therapy and progress to transplantation. ClagalsiR targets claudin-3, a unique mechanism that boosts bicarbonate-rich bile, reduces toxic bile acids and protects liver tissue. Preclinical data show clear reductions in bile acid load and injury. Backed by Swiss innovation programs, CALDRE is expanding a pipeline in tight-junction modulation and advancing toward IND-enabling studies.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
01.10.2025
In vivo proof-of-concept in established disease model
01.10.2025
Pharmacologic in vivo proof-of-concept in pre-established cholestasis disease model
03.09.2025
Incorporated company CALDRE Ltd.
01.06.2025
Completed therapeutic lead candidate screening
30.01.2025
Foundational IP enters national phase
No Jobs
No videos and documents
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
CALDRE AG
CALDRE develops innovative liver disease therapeutics.
Website:
www.caldre.ch/
Headquarter:
Bern
Foundation Date:
September 2025
Technology:
- Biotech
Sectors:
- Biotech
- Drug development platforms
- Inflammation
- Research and development
- Organ and Tissues
- Surgery
Support received
